KRAS and neoplasm: Figure 1 illustrates for the first time: (1) the tissue‐specific differences in ultralow frequency KRAS and PIK3CA mutation levels, (2) the remarkable prevalence of low‐frequency mutant populations, and (3) in some cases, a suprising overlap in the frequency distributions between normal and tumor.